[Leish-l] Breakthrough in treatment of VL & MCL

[Jeffrey Shaw]

Dear colleagues,
>
> We have the pleasure to share with you that Gilead Sciences, Inc. has
> announced offically WHO with the reduction of the price of AmBisome to
US$20
> per vial  to Public Sector Agencies of all Developing Countries, for the
> treatment of visceral and mucosal leishmaniasis. This important
achievement
> will have enormous impact worldover in the control of this neglected
tropical disease.
>
> The reduction is effective from now. Public Sector Agencies interested can

> enter directly in contact with:
>
> Ms. Lorraine Fitzpatrick
> AmBisome Access Programme
> Gilead Sciences, Ltd
> Unit 13, Stillorgan Industrial Park
> Blackrock Co. Dublin, IRELAND
>
> Tel:      +353-1-2952729
> Fax: +353-1-2952449
> Email: lorraine.fitzpatrick at gilead.com
>
> Please, circulate this important information.
>
> Yours sincerely,
>
> Dr Jorge Alvar
>
> Medical Officer (Leishmaniasis Control)
> Control of Neglected Tropical Diseases
> Innovative and Intensified Disease Management
> Communicable Diseases Cluster
> World Health Organization
> 20, Avenue Appia; CH-1211  Geneva 27
> Tel.        +41 22 791 3870
> Fax     +41 22 791 4877
> e-mail: alvarj at who.int
-------------- next part --------------
An HTML attachment was scrubbed...
URL: http://lineu.icb.usp.br/pipermail/leish-l/attachments/20070521/d1d748c7/attachment.html